Skip Navigation


International Immunology Advance Access originally published online on October 31, 2006
International Immunology 2006 18(12):1759-1769; doi:10.1093/intimm/dxl110
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/12/1759    most recent
dxl110v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Petkova, S. B.
Right arrow Articles by Roopenian, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petkova, S. B.
Right arrow Articles by Roopenian, D. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Published by Oxford University Press 2006.

Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease

Stefka B. Petkova1, Shreeram Akilesh1,4, Thomas J. Sproule1, Gregory J. Christianson1, Hana Al Khabbaz1, Aaron C. Brown1, Leonard G. Presta2,5, Y. Gloria Meng3 and Derry C. Roopenian1

1 Jackson Laboratory, Bar Harbor, ME 04609, USA
2 Department of Antibody Engineering, Genentech Inc., South San Francisco, CA, USA
3 Department of Assay and Automation Technology, Genentech Inc., South San Francisco, CA, USA
4 Present address: Department of Pathology, Washington University, St Louis, MO, USA
5 Present address: Schering-Plough Biopharma, Palo Alto, CA, USA

Correspondence to: D. C. Roopenian; E-mail: dcr{at}jax.org

The MHC class I-like Fc receptor FcRn plays an essential role in extending the half-life (t1/2) of IgG antibodies and IgG-Fc-based therapeutics in the circulation. The goal of this study was to analyze the effect of human IgG1 (hIgG1) antibodies with enhanced in vitro binding to FcRn on their in vivo t1/2 in mice expressing human FcRn (hFcRn). Mutants of the humanized monoclonal Herceptin antibody (Hu4D5-IgG1), directed against human epidermal growth factor receptor 2 (p185 HER2), show altered pH-dependent binding to hFcRn in vitro. Two engineered IgG1 mutants (N434A and T307A/E380A/N434A) showed a considerably extended t1/2 in vivo compared with wild-type antibody in mice expressing an hFcRn transgene (Tg) but not in mice expressing the endogenous mouse FcRn. The efficiency of hFcRn-mediated protection was dependent on hFcRn Tg copy number. Moreover, when injected into FcRn-humanized mice at a concentration sufficient to partially saturate hFcRn, the engineered IgG1 mutants with an extended serum t1/2 were most effective in reducing the t1/2 of a tracer hIgG1 antibody. Finally, administration of mutant with high binding to hFcRn ameliorated arthritis induced by passive transfer with human pathogenic plasma. These results indicate that Fc regions modified for high binding affinity to hFcRn increases serum persistence of therapeutic antibodies, that the same approach can be exploited as an anti-autoimmune therapy to promote the clearance of endogenous pathogenic IgG and that FcRn-humanized mice are a promising surrogate for hIgG therapeutic development.

Keywords: antibody, FcRn transgenic mice, neonatal receptor FcRn, rheumatoid arthritis

Transmitting editor: E. Simpson


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
Y. A. Yeung, M. K. Leabman, J. S. Marvin, J. Qiu, C. W. Adams, S. Lien, M. A. Starovasnik, and H. B. Lowman
Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates
J. Immunol., June 15, 2009; 182(12): 7663 - 7671.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. W. Schneider, T. Heitner, B. Alicke, D. R. Light, K. McLean, N. Satozawa, G. Parry, J. Yoo, J. S. Lewis, and R. Parry
In Vivo Biodistribution, PET Imaging, and Tumor Accumulation of 86Y- and 111In-Antimindin/RG-1, Engineered Antibody Fragments in LNCaP Tumor-Bearing Nude Mice
J. Nucl. Med., March 1, 2009; 50(3): 435 - 443.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. P. Montoyo, C. Vaccaro, M. Hafner, R. J. Ober, W. Mueller, and E. S. Ward
Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice
PNAS, February 24, 2009; 106(8): 2788 - 2793.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
X. Liu, L. Ye, Y. Bai, H. Mojidi, N. E. Simister, and X. Zhu
Activation of the JAK/STAT-1 Signaling Pathway by IFN-{gamma} Can Down-Regulate Functional Expression of the MHC Class I-Related Neonatal Fc Receptor for IgG
J. Immunol., July 1, 2008; 181(1): 449 - 463.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. R. Mezo, K. A. McDonnell, C. A. T. Hehir, S. C. Low, V. J. Palombella, J. M. Stattel, G. D. Kamphaus, C. Fraley, Y. Zhang, J. A. Dumont, et al.
Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn
PNAS, February 19, 2008; 105(7): 2337 - 2342.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Akilesh, G. J. Christianson, D. C. Roopenian, and A. S. Shaw
Neonatal FcR Expression in Bone Marrow-Derived Cells Functions to Protect Serum IgG from Catabolism
J. Immunol., October 1, 2007; 179(7): 4580 - 4588.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
X. Liu, L. Ye, G. J. Christianson, J.-Q. Yang, D. C. Roopenian, and X. Zhu
NF-{kappa}B Signaling Regulates Functional Expression of the MHC Class I-Related Neonatal Fc Receptor for IgG via Intronic Binding Sequences
J. Immunol., September 1, 2007; 179(5): 2999 - 3011.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.